Beyond market trends, investors keen on maximizing returns delve into the world of stock picking. The right selections can be instrumental in catapulting your wealth.
The closing price of Recursion Pharmaceuticals Inc (NASDAQ: RXRX) was $24.01M for the day, up 32058196% from the previous closing price of $5.11. In other words, the price has increased by $32058196 from its previous closing price. On the day, 32.06 million shares were traded.
Ratios:
Our analysis of RXRX’s different ratios will help us gain a deeper understanding of the company. For the most recent quarter (mrq), Quick Ratio is recorded 4.11 and its Current Ratio is at 4.11. In the meantime, Its Debt-to-Equity ratio is 0.10 whereas as Long-Term Debt/Eq ratio is at 0.08.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Morgan Stanley on May 22, 2023, initiated with a Equal-Weight rating and assigned the stock a target price of $8.
On March 16, 2023, Needham started tracking the stock assigning a Buy rating and target price of $17.
On September 16, 2022, KeyBanc Capital Markets started tracking the stock assigning a Overweight rating and target price of $20.KeyBanc Capital Markets initiated its Overweight rating on September 16, 2022, with a $20 target price.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on Mar 27 ’25 when Gibson Christopher sold 138,574 shares for $6.04 per share. The transaction valued at 836,987 led to the insider holds 1,117,450 shares of the business.
Gibson Christopher bought 138,574 shares of RXRX for $836,987 on Mar 27 ’25. On Mar 05 ’25, another insider, Gibson Christopher, who serves as the Chief Executive Officer of the company, sold 20,000 shares for $6.58 each. As a result, the insider received 131,600 and left with 1,256,024 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, RXRX now has a Market Capitalization of 2044669952. For the stock, the TTM Price-to-Sale (P/S) ratio is 34.20 while its Price-to-Book (P/B) ratio in mrq is 2.19.
Stock Price History:
Over the past 52 weeks, RXRX has reached a high of $12.36, while it has fallen to a 52-week low of $3.79. The 50-Day Moving Average of the stock is 2.13%, while the 200-Day Moving Average is calculated to be -20.97%.
Shares Statistics:
A total of 399.15M shares are outstanding, with a floating share count of 310.78M. Insiders hold about 23.55% of the company’s shares, while institutions hold 60.53% stake in the company.
Dividends & Splits
Against a Trailing Annual Dividend Yield of 0.0
Earnings Estimates
Investors are eagerly awaiting the insights provided by 6.0 analysts currently analyzing and rating the stock of Recursion Pharmaceuticals Inc (RXRX).The consensus estimate for the next quarter is -$0.31, with high estimates of -$0.27 and low estimates of -$0.35.
Analysts are recommending an EPS of between -$1.23 and -$1.64 for the fiscal current year, implying an average EPS of -$1.46. EPS for the following year is -$1.14, with 9.0 analysts recommending between -$0.81 and -$1.46.
Revenue Estimates
It is expected that $90B in revenue will be generated in the current quarter, according to 6 analysts. It ranges from a high estimate of $27.7M to a low estimate of $5M. As of the current estimate, Recursion Pharmaceuticals Inc’s year-ago sales were $14.42MFor the next quarter, 6 analysts are estimating revenue of $20.03M. There is a high estimate of $28.9M for the next quarter, whereas the lowest estimate is $5M.
A total of 9 analysts have provided revenue estimates for RXRX’s current fiscal year. The highest revenue estimate was $115.5M, while the lowest revenue estimate was $44.85M, resulting in an average revenue estimate of $70.98M. In the same quarter a year ago, actual revenue was $58.84MBased on 9 analysts’ estimates, the company’s revenue will be $106.78M in the next fiscal year. The high estimate is $208.4M and the low estimate is $45M.
